Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 12 of 87 · 4174 articles
The study helps explain how granulomas—linked to more severe Crohn’s disease—might form by repurposing lymphoid follicle macrophages, pointing to cellular programs and signals that could be relevant for future biomarkers...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Ustekinumab. The original article is from BMC Gastroenterology.
This study supports intestinal ultrasound as a noninvasive, accurate way to detect small-bowel Crohn's activity in many pediatric patients, which could reduce reliance on MRI for routine monitoring. It highlights...
This study suggests mirikizumab can maintain endoscopic and symptomatic improvements for up to two years in many patients with Crohn’s disease, and that IV reinduction can recover response in a subset of 1-year...
Faster, more sensitive capsule endoscopy reading could catch more Crohn’s-related ulcers that might otherwise be missed and reduce the time clinicians spend reviewing long video exams. However, AI increased false...
Starting biologic therapy within six months of Crohn’s diagnosis was associated with substantially higher rates of steroid-free remission at one year and less steroid dependence, suggesting earlier treatment could...
Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Inflammatory bowel disease, and Pediatrics and family. The original article is from pubmed.ncbi.nlm.nih.gov.
Based on the title and source metadata, this appears to be an opinion or commentary related to Inflammatory bowel disease and Medications. The original article is from Internal medicine journal.
The study is collecting genetic and clinical data to identify genes that may contribute to IBD risk across populations — information that could inform future research, risk prediction, and understanding of disease...
This national pediatric IBD network aims to collect clinical data and biological samples to study causes of early-onset IBD, track outcomes including intestinal healing and growth, and improve treatment strategies — work...
People with UC and PSC have limited study data on microbiome-targeted therapies; this trial asks whether short-course oral vancomycin is feasible and safe in this specific group and will look for early signals in...
Adherence to biologic therapy can affect how well treatment controls IBD; understanding whether self-administered subcutaneous vedolizumab has different adherence than IV infusion could influence treatment choices and...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Blood Test, and Tests and monitoring. The original article is from Canadian journal of gastroenterology &...
Noninvasive fecal tests can help detect intestinal inflammation without repeated endoscopy and support treat-to-target care. Better biomarkers could mean earlier treatment changes and less invasive monitoring for people...
This review directly addresses whether switching from originator infliximab to a biosimilar affects disease control or safety in children with IBD — a common practical concern for families and clinicians. Its pooled data...
The study documents shifting real-world prescribing for newly diagnosed IBD in Germany, with more biologic use and less mesalazine/thiopurine in recent years — changes that could affect treatment expectations and access.
The analysis suggests that some biologic and small-molecule therapies work differently depending on whether Crohn's disease affects the ileum, colon, or both — information that could help tailor long-term treatment...
Accurate, consistent severity grading at diagnosis shapes initial treatment decisions in Crohn’s disease. AI that can reproduce expert severity assessments from small labeled datasets could help standardize grading and...
The piece explains emerging strategies that aim to act earlier in the disease process (immune-cell modulation, barrier repair, microbiome change) than current anti-TNF drugs, which could matter to patients seeking future...
People with ulcerative colitis may be interested because the review explains how the gut microbiome and its metabolites could influence disease and evaluates whether traditional Chinese medicines might modify those...
This study helps pinpoint which gut cell types and regulatory DNA regions are most likely to mediate genetic risk for Crohn’s disease, which can guide future research toward relevant cells and pathways.
If validated, early bedside ultrasound changes could let clinicians identify within days whether steroids or biologics are working, enabling faster treatment adjustments and potentially avoiding prolonged ineffective...
Families and clinicians deciding on a first biologic for a child with ulcerative colitis need to know which drugs have pediatric-specific evidence. This review shows infliximab has the strongest pediatric data, while...
Cure8 could only read part of this source from American Journal of Therapeutics, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and...
People with IBD or their clinicians may see signals suggesting certain drugs are more often reported with ulcerative colitis; this study combines adverse‑event reports with gene‑expression comparisons to help prioritize...
Researchers exploring new anti-inflammatory or metabolism-targeting approaches for UC might view KA as a candidate molecule that modulates arginine–polyamine metabolism, which could point to new drug-discovery...
Patients with IBD—particularly those on anti‑TNF therapy and older adults—may have lower and faster‑waning antibody responses after mRNA COVID‑19 vaccination, which could affect timing or need for additional vaccine...
If local norepinephrine promotes neutrophil‑driven inflammation in UC, that could help explain disease progression in some patients and point to biomarkers (ADRB2‑rich neutrophils) that might predict response to anti‑TNF...
STAT3 is a central immune signaling molecule implicated in ulcerative colitis; understanding its dual roles could influence future biomarker research and therapies for UC. The review highlights why STAT3’s...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Biomarkers. The original article is from Gastroenterology.
Researchers are exploring whether ketone metabolism or ketogenic diets could affect inflammation, barrier function, and the microbiome — all central to IBD. Patients may see interest because dietary approaches and...
If you or your child is starting exclusive enteral nutrition (EEN) for pediatric Crohn’s disease, this review explains why outcomes vary and what tests and research might help predict who will benefit.
This work organizes preclinical evidence connecting Atractylodes macrocephala constituents to intestinal barrier protection, immune modulation, and microbiota changes relevant to ulcerative colitis—useful for researchers...
Up to one-third of people with IBD in clinical remission still have IBS-like symptoms that reduce quality of life and are not helped by anti-inflammatory treatments.
This study reports real-world short-term outcomes after colectomy for IBD at a tertiary New Zealand centre, including complication rates and how often restorative surgery (ileal pouch) was later performed—information...
Postoperative recurrence after ileocolonic resection is common and identifying who is at higher risk helps guide postoperative monitoring and decisions about early prophylactic therapy.
Food insecurity was linked with higher odds of having IBD and other GI conditions in a large U.S. survey, and many affected people lacked benefits or cancer screening. This matters because access to sufficient nutritious...
Patients with fibrostenosing Crohn’s disease face progressive strictures and limited targeted treatments; data from STENOVA’s OLE and the planned NOV‑ERA trial could advance therapies that target both inflammation and...
If confirmed, a pretreatment mucosal JAK‑dependent inflammatory signature could help predict who will respond to tofacitinib, potentially guiding therapy choice and avoiding ineffective treatment for people with...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from Internal medicine journal.
Faecal urgency is a frequent, disabling symptom in Crohn's disease that was common in this cohort and tied to poorer quality of life, mental-health burden, and more healthcare use over one year.
Pulmonary nodules appear more frequently in people with Crohn’s disease and have distinct patterns over time. Knowing which factors predict nodule burden can help clinicians prioritize monitoring and interpret chest...
Rising IBD incidence and prevalence in Asia mean more people will need long-term care, specialist services, and health-system planning. Understanding regional trends helps patients and policymakers anticipate resource...
Cardiorespiratory fitness (VO2peak) is an important health measure and may be relevant for people with IBD. Having accurate, simpler ways to estimate VO2peak makes it easier to assess fitness in clinic or studies without...
Perianal fistulas cause significant morbidity and often need both medical and surgical treatments. Newer drug options and updated guideline support earlier use of advanced therapies, which may improve healing and reduce...
Cure8 found this source from youtube.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab. Open the original article for the full details.
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from navlindaily.com.
